Sophiris Bio Inc (NASDAQ:SPHS) reported fourth quarter and full year 2016 financial results and key corporate highlights. Key Corporate Highlights: Advanced Topsalysin (PRX302) …
In a research released Friday, Maxim analyst Jason Kolbert reiterated a Buy rating on shares of Sophiris Bio Inc (NASDAQ:SPHS), with a price target …
Sophiris Bio Inc (NASDAQ:SPHS) shares are rising almost 17% on back of Rodman & Renshaw analyst Joseph Pantginis initiating coverage on SPHS with …
In a research report issued today, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on shares of Sophiris Bio Inc (NASDAQ:SPHS) with …
Sophiris Bio Inc (NASDAQ:SPHS) announced financial results for the three and nine months ended September 30, 2016. Business Highlights: On August 26, 2016, …
By Dana Lyons A key gauge of biotechnology stocks is testing major trendline support presently – can it hold yet again? When this …
Roth Capital analyst Joseph Pantginis initiates coverage on shares of Sophiris Bio Inc (NASDAQ:SPHS) as the analyst provides a closer look at the …
Sophiris Bio Inc. (NASDAQ:SPHS), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced the pricing of an underwritten public …
Sophiris Bio Inc (NASDAQ:SPHS), a biopharmaceutical company developing PRX302 (topsalysin) for the treatment of urological diseases, today announced that it intends to offer and …
Biotech firm Sophiris Bio Inc (NASDAQ:SPHS) just posted second-quarter results as well as an update on its progress for its clinical development program. …
